Medical Access Program for Patritumab Deruxtecan

This is a Medical Access Program which will be available to adult patients in the US with metastatic or locally advanced EGFRm NSCLC who have received at least 2 prior systemic therapies, who have no alternative commercially available treatment options, and are not able to enter a clinical trial. In this Medical Access Program, eligible patients will be treated with HER3-DXd and will continue to receive treatment until any of the following occurs: * Disease progression * Unacceptable toxicity * The benefit-risk no longer favors the individual * HER3-DXd becomes commercially available in the US and reimbursement is approved for the concerned indication of the Medical Access Program. * Withdrawal of consent * Pregnancy * Physician discretion * Death